-
1
-
-
0032855543
-
Troglitazone-induced heart and adipose tissue cell proliferation in mice
-
Breider MA, Gough AW, Haskins JR, Sobocinski G, de la Iglesia FA. Troglitazone-induced heart and adipose tissue cell proliferation in mice. Toxicol Pathol 1999;27:545-52.
-
(1999)
Toxicol Pathol
, vol.27
, pp. 545-552
-
-
Breider, M.A.1
Gough, A.W.2
Haskins, J.R.3
Sobocinski, G.4
de la Iglesia, F.A.5
-
2
-
-
10544229796
-
Activation of the nuclear receptor peroxisome proliferators-activated receptor gamma promotes brown adipocyte differentiation
-
Tai TA, Jennermann C, Brown KK, Oliver BB, MacGinnitie MA, Wilkison WO, et al. Activation of the nuclear receptor peroxisome proliferators-activated receptor gamma promotes brown adipocyte differentiation. J Biol Chem 1996;271:20090-114.
-
(1996)
J Biol Chem
, vol.271
, pp. 20090-20114
-
-
Tai, T.A.1
Jennermann, C.2
Brown, K.K.3
Oliver, B.B.4
MacGinnitie, M.A.5
Wilkison, W.O.6
-
3
-
-
0028598170
-
Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat
-
Lee MK, Miles PD, Khoursheed M, Gao KM, Moossa AR, Olefsky JM. Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes 1994;43:1435-40.
-
(1994)
Diabetes
, vol.43
, pp. 1435-1440
-
-
Lee, M.K.1
Miles, P.D.2
Khoursheed, M.3
Gao, K.M.4
Moossa, A.R.5
Olefsky, J.M.6
-
4
-
-
0037459356
-
PPARs of the heart
-
Kelly DP. PPARs of the heart. Circ Res 2003;92:482-4.
-
(2003)
Circ Res
, vol.92
, pp. 482-484
-
-
Kelly, D.P.1
-
5
-
-
0029774572
-
Cardioprotective effects of troglitazone in streptozotocin-induced diabetic rats
-
Shimabukuro M, Higa S, Shinzato T, Nagamine F, Komiya I, Takasu N. Cardioprotective effects of troglitazone in streptozotocin-induced diabetic rats. Metabolism 1996;45:1168-73.
-
(1996)
Metabolism
, vol.45
, pp. 1168-1173
-
-
Shimabukuro, M.1
Higa, S.2
Shinzato, T.3
Nagamine, F.4
Komiya, I.5
Takasu, N.6
-
6
-
-
0031888958
-
PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines
-
Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391:82-6.
-
(1998)
Nature
, vol.391
, pp. 82-86
-
-
Jiang, C.1
Ting, A.T.2
Seed, B.3
-
7
-
-
0034730794
-
Peroxisome proliferators-activated receptor activators inhibit lipoplysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes
-
Takano H, Nagai T, Asakawa M, Toyozaki T, Oka T, Komuro I, et al. Peroxisome proliferators-activated receptor activators inhibit lipoplysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes. Circ Res 2000;87:596-602.
-
(2000)
Circ Res
, vol.87
, pp. 596-602
-
-
Takano, H.1
Nagai, T.2
Asakawa, M.3
Toyozaki, T.4
Oka, T.5
Komuro, I.6
-
8
-
-
0141788713
-
Troglitazone administration limits infarct size by reduced phosphorylation of canine myocardial connexin43 proteins
-
Lee TM, Chou TF. Troglitazone administration limits infarct size by reduced phosphorylation of canine myocardial connexin43 proteins. Am J Physiol Heart Circ Physiol 2003;285:H1650-9.
-
(2003)
Am J Physiol Heart Circ Physiol
, vol.285
-
-
Lee, T.M.1
Chou, T.F.2
-
9
-
-
0034646419
-
Troglitazone improves recovery of left ventricular function after regional ischemia in pigs
-
Zhu P, Lu L, Xu Y, Schwartz GG. Troglitazone improves recovery of left ventricular function after regional ischemia in pigs. Circulation 2000;101:1165-71.
-
(2000)
Circulation
, vol.101
, pp. 1165-1171
-
-
Zhu, P.1
Lu, L.2
Xu, Y.3
Schwartz, G.G.4
-
10
-
-
11144344187
-
PPARγ agonist rosiglitazone ameliorates ventricular dysfunction in experimental chronic mitral regurgitation
-
Nemoto S, Razeghi P, Ishiyama M, De Freitas G, Taegtmeyer H, Carbello BA, et al. PPARγ agonist rosiglitazone ameliorates ventricular dysfunction in experimental chronic mitral regurgitation. Am J Physiol Heart Circ Physiol 2004;288:H77-82.
-
(2004)
Am J Physiol Heart Circ Physiol
, vol.288
-
-
Nemoto, S.1
Razeghi, P.2
Ishiyama, M.3
De Freitas, G.4
Taegtmeyer, H.5
Carbello, B.A.6
-
11
-
-
13944284526
-
PPARγ activation fails to provide myocardial protection in ischemia and reperfusion in pigs
-
Xu Y, Gen M, Lu L, et al. PPARγ activation fails to provide myocardial protection in ischemia and reperfusion in pigs. Am J Physiol Heart Circ Physiol 2005;288:H1314-23.
-
(2005)
Am J Physiol Heart Circ Physiol
, vol.288
-
-
Xu, Y.1
Gen, M.2
Lu, L.3
-
12
-
-
0037453063
-
Glitazones and heart failure: Critical appraisal for the clinician
-
Wang CH, Weisel RD, Liu PP, Fedak PWM, Verma S. Glitazones and heart failure: critical appraisal for the clinician. Circulation 2003;107:1350-4.
-
(2003)
Circulation
, vol.107
, pp. 1350-1354
-
-
Wang, C.H.1
Weisel, R.D.2
Liu, P.P.3
Fedak, P.W.M.4
Verma, S.5
-
13
-
-
10744221639
-
Thiazolidine use, fluid retention, and congestive heart failure. A consensus statement from the Ameicarn Heart Association and the American Diabetes Association
-
Nesto RW, Ball D, Bonow RO, Fonseca V, Grundy SM, Horton ES, et al. Thiazolidine use, fluid retention, and congestive heart failure. A consensus statement from the Ameicarn Heart Association and the American Diabetes Association. Diabetes Care 2004;27:256-63.
-
(2004)
Diabetes Care
, vol.27
, pp. 256-263
-
-
Nesto, R.W.1
Ball, D.2
Bonow, R.O.3
Fonseca, V.4
Grundy, S.M.5
Horton, E.S.6
-
14
-
-
0025865760
-
A canine model of chronic heart failure produced by multiple sequential coronary microembolizations
-
Sabbah HN, Stein PD, Kono T, Gheorghiade M, Levine TB, Jafri S, et al. A canine model of chronic heart failure produced by multiple sequential coronary microembolizations. Am J Physiol 1991;260:H1379-84.
-
(1991)
Am J Physiol
, vol.260
-
-
Sabbah, H.N.1
Stein, P.D.2
Kono, T.3
Gheorghiade, M.4
Levine, T.B.5
Jafri, S.6
-
15
-
-
0028261043
-
Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction
-
Sabbah HN, Shimoyama H, Kono T, Gupta RC, Sharov VG, Scicli G, Levine TB, et al. Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation 1994;89:2852-9.
-
(1994)
Circulation
, vol.89
, pp. 2852-2859
-
-
Sabbah, H.N.1
Shimoyama, H.2
Kono, T.3
Gupta, R.C.4
Sharov, V.G.5
Scicli, G.6
Levine, T.B.7
-
16
-
-
0033864582
-
Peroxisome proliferator-activated receptor r ligands inhibit development of atherosclerosis in LDL receptor-deficient mice
-
Li AC, Brown KK, Silvestre MJ, Wilson TM, Palinski W, Glass C. Peroxisome proliferator-activated receptor r ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2000;106:523-31.
-
(2000)
J Clin Invest
, vol.106
, pp. 523-531
-
-
Li, A.C.1
Brown, K.K.2
Silvestre, M.J.3
Wilson, T.M.4
Palinski, W.5
Glass, C.6
-
17
-
-
16844378356
-
Pressure measurement
-
Grossman W, Baim DS editors, Philadelphia: Lea & Febiger;
-
Grossman W: Pressure measurement. In: Grossman W, Baim DS editors. Cardiac catheterization, angiography, and intervention. Philadelphia: Lea & Febiger; 1991. p. 123.
-
(1991)
Cardiac catheterization, angiography, and intervention
, pp. 123
-
-
Grossman, W.1
-
18
-
-
0031003230
-
Effects of angiotension-converting enzyme inhibitors and angiotension II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotension II type 2 receptors
-
Liu Yh, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, et al. Effects of angiotension-converting enzyme inhibitors and angiotension II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotension II type 2 receptors. J Clin Invest 1997;99:1926-35.
-
(1997)
J Clin Invest
, vol.99
, pp. 1926-1935
-
-
Liu, Y.1
Yang, X.P.2
Sharov, V.G.3
Nass, O.4
Sabbah, H.N.5
Peterson, E.6
-
19
-
-
0035942264
-
Cytokines and cytokine receptors in advanced heart failure: An analysis of the cytokine database from the Vesnarinone Trial (VEST)
-
Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone Trial (VEST). Circulation 2001;103:2055-9.
-
(2001)
Circulation
, vol.103
, pp. 2055-2059
-
-
Deswal, A.1
Petersen, N.J.2
Feldman, A.M.3
Young, J.B.4
White, B.G.5
Mann, D.L.6
-
20
-
-
0029871896
-
Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the Studies of Left Ventricular Dysfunction (SOLVD)
-
Apr
-
Torre-Aminone G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996;27 5:1201-6, Apr.
-
(1996)
J Am Coll Cardiol
, vol.27
, Issue.5
, pp. 1201-1206
-
-
Torre-Aminone, G.1
Kapadia, S.2
Benedict, C.3
Oral, H.4
Young, J.B.5
Mann, D.L.6
-
21
-
-
0033614816
-
Safety and efficacy of a soluble p75 tumor necrosis factor receptor (etanercept) in patients with advanced heart failure
-
Deswal A, Bozkurt B, Seta Y, Parilti-Eiswirth S, Hayes FA, Blosch C, et al. Safety and efficacy of a soluble p75 tumor necrosis factor receptor (etanercept) in patients with advanced heart failure. Circulation 1999;99:3224-6.
-
(1999)
Circulation
, vol.99
, pp. 3224-3226
-
-
Deswal, A.1
Bozkurt, B.2
Seta, Y.3
Parilti-Eiswirth, S.4
Hayes, F.A.5
Blosch, C.6
-
22
-
-
0035957036
-
Results of targeted anti-tumor necrosis factory therapy with entanercept (ENBREL) in patients with advanced heart failure
-
Bozkurt B, Torre-Amione G, Warren MS, Whitmore J, Soran OZ, Feldman AM, et al. Results of targeted anti-tumor necrosis factory therapy with entanercept (ENBREL) in patients with advanced heart failure. Circulation 2001;103:1044-7.
-
(2001)
Circulation
, vol.103
, pp. 1044-1047
-
-
Bozkurt, B.1
Torre-Amione, G.2
Warren, M.S.3
Whitmore, J.4
Soran, O.Z.5
Feldman, A.M.6
-
23
-
-
0032507428
-
Randomized investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy
-
Sliwa K, Skudicky D, Candy G, Wisenbaugh T, Sareli P. Randomized investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet 1998;351:1091-3.
-
(1998)
Lancet
, vol.351
, pp. 1091-1093
-
-
Sliwa, K.1
Skudicky, D.2
Candy, G.3
Wisenbaugh, T.4
Sareli, P.5
-
24
-
-
11144355760
-
Targeted anticytokine therapy in patients with chronic heart failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)
-
Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004;109:1594-602.
-
(2004)
Circulation
, vol.109
, pp. 1594-1602
-
-
Mann, D.L.1
McMurray, J.J.2
Packer, M.3
Swedberg, K.4
Borer, J.S.5
Colucci, W.S.6
-
25
-
-
0031886864
-
The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation
-
Ricote M, Li AC, Wilson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998;391:79-82.
-
(1998)
Nature
, vol.391
, pp. 79-82
-
-
Ricote, M.1
Li, A.C.2
Wilson, T.M.3
Kelly, C.J.4
Glass, C.K.5
-
26
-
-
0032972793
-
Hemodynamic basis for the acute cardiac effects of troglitazone in isolated perfused rat hearts
-
Shimoyama M, Ogino K, Tanaka Y, Ikeda T, Hisatome I. Hemodynamic basis for the acute cardiac effects of troglitazone in isolated perfused rat hearts. Diabetes 1999;48:609-15.
-
(1999)
Diabetes
, vol.48
, pp. 609-615
-
-
Shimoyama, M.1
Ogino, K.2
Tanaka, Y.3
Ikeda, T.4
Hisatome, I.5
-
27
-
-
0031054699
-
Cardiac and glycemic benefits of troglitazone treatment in NIDDM: The troglitazone study group
-
Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM: the troglitazone study group. Diabetes 1997;46:433-9.
-
(1997)
Diabetes
, vol.46
, pp. 433-439
-
-
Ghazzi, M.N.1
Perez, J.E.2
Antonucci, T.K.3
Driscoll, J.H.4
Huang, S.M.5
Faja, B.W.6
-
28
-
-
0033520304
-
Peroxisome proliferators-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway
-
Delerive P, Martin-Nizard F, Chinetti G, Trottein F, Fruchart JC, Najib J, et al. Peroxisome proliferators-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 1999;85:394-402.
-
(1999)
Circ Res
, vol.85
, pp. 394-402
-
-
Delerive, P.1
Martin-Nizard, F.2
Chinetti, G.3
Trottein, F.4
Fruchart, J.C.5
Najib, J.6
-
29
-
-
0029142479
-
Blood pressure lowering by pioglitazome. Evidence for a direct vascular effect
-
Buchanan TA, Meehan WP, Jeng YY, Yang D, Chan TM, Nadler JL, et al. Blood pressure lowering by pioglitazome. Evidence for a direct vascular effect. J Clin Invest 1995;96:354-60.
-
(1995)
J Clin Invest
, vol.96
, pp. 354-360
-
-
Buchanan, T.A.1
Meehan, W.P.2
Jeng, Y.Y.3
Yang, D.4
Chan, T.M.5
Nadler, J.L.6
-
30
-
-
0037066014
-
Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo
-
Asakawa M, Takano H, Nagai T, Uozumi H, Hasegawa H, Kubuto N, et al. Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 2002;105:1240-6.
-
(2002)
Circulation
, vol.105
, pp. 1240-1246
-
-
Asakawa, M.1
Takano, H.2
Nagai, T.3
Uozumi, H.4
Hasegawa, H.5
Kubuto, N.6
-
31
-
-
34247111460
-
Thiazolidinedione, Tanabe-174 (LY282449), in the rat and dog
-
Williams GD, Deldar A, Jordan WH, Gries C, Long GG, Dimarchi RD. Thiazolidinedione, Tanabe-174 (LY282449), in the rat and dog. Diabetes 1993;42 Suppl:59A.
-
(1993)
Diabetes
, vol.42
, Issue.SUPPL. 59A
-
-
Williams, G.D.1
Deldar, A.2
Jordan, W.H.3
Gries, C.4
Long, G.G.5
Dimarchi, R.D.6
-
32
-
-
0034598979
-
Troglitazone does not initiate hypertrophy but can sensitize cardiomyocytes to grow effects the serum
-
Bell D, McDermott BJ. Troglitazone does not initiate hypertrophy but can sensitize cardiomyocytes to grow effects the serum. Eur J Pharmacol 2000;390:237-44.
-
(2000)
Eur J Pharmacol
, vol.390
, pp. 237-244
-
-
Bell, D.1
McDermott, B.J.2
-
33
-
-
0032855543
-
Troglitazone-induced heart and adipose tissue cell proliferation in mice
-
Breider MA, Gough AW, Haskins JR, Sobocinski G, de la Iglesia FA. Troglitazone-induced heart and adipose tissue cell proliferation in mice. Toxicol Pathol 1999;27:545-52.
-
(1999)
Toxicol Pathol
, vol.27
, pp. 545-552
-
-
Breider, M.A.1
Gough, A.W.2
Haskins, J.R.3
Sobocinski, G.4
de la Iglesia, F.A.5
-
34
-
-
0033605677
-
Peroxisome proliferators- activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo
-
Xin X, Yang S, Kowalski J, Gerritsen ME. Peroxisome proliferators- activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 1999;274:9116-21.
-
(1999)
J Biol Chem
, vol.274
, pp. 9116-9121
-
-
Xin, X.1
Yang, S.2
Kowalski, J.3
Gerritsen, M.E.4
-
35
-
-
0033546190
-
Endothelial cell apoptosis induced by the peroxisome proliferators-activated receptor (PPAR) ligand 15-deoxy-Delta 12, 14-prostaglandin J2
-
Bishop-Bailey D, Hla T. Endothelial cell apoptosis induced by the peroxisome proliferators-activated receptor (PPAR) ligand 15-deoxy-Delta 12, 14-prostaglandin J2. J Biol Chem 1999;274:17042-8.
-
(1999)
J Biol Chem
, vol.274
, pp. 17042-17048
-
-
Bishop-Bailey, D.1
Hla, T.2
-
36
-
-
0037453063
-
Glitazones and heart failure: Critical appraisal for the clinician
-
Wang CH, Weisel RD, Liu PP, Fedak PWM, Verma S. Glitazones and heart failure: critical appraisal for the clinician. Circulation 2003;107:1350-4.
-
(2003)
Circulation
, vol.107
, pp. 1350-1354
-
-
Wang, C.H.1
Weisel, R.D.2
Liu, P.P.3
Fedak, P.W.M.4
Verma, S.5
-
37
-
-
0036218614
-
Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure
-
Wooltron E. Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure. Can Medical Assoc J 2002;166:219.
-
(2002)
Can Medical Assoc J
, vol.166
, pp. 219
-
-
Wooltron, E.1
-
38
-
-
0344230806
-
Tolerability profile of pioglitazone in combination with a sulfonyluria or metformin in controlled clinical trials
-
Belcher GL, Michel JL. Tolerability profile of pioglitazone in combination with a sulfonyluria or metformin in controlled clinical trials. Diabetes 2001;49 Suppl 2:A416.
-
(2001)
Diabetes
, vol.49
, Issue.SUPPL. 2
-
-
Belcher, G.L.1
Michel, J.L.2
-
39
-
-
0000469315
-
Adverse events with pioglitazone
-
Aronoff SL. Adverse events with pioglitazone. Diabetes 2000;49 Suppl 1:A340.
-
(2000)
Diabetes
, vol.49
, Issue.SUPPL. 1
-
-
Aronoff, S.L.1
-
40
-
-
0036833805
-
A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes
-
St. John Sutton M, Rendell M, Dandona P, Dole JF, Murphy K, Patwardhan R, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002;25:2058-64.
-
(2002)
Diabetes Care
, vol.25
, pp. 2058-2064
-
-
St. John Sutton, M.1
Rendell, M.2
Dandona, P.3
Dole, J.F.4
Murphy, K.5
Patwardhan, R.6
-
41
-
-
0034406481
-
PPAR-gamma agonists: Therapeutic role in diabetes, inflammation and cancer
-
Murphy GJ, Holder JC. PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol Sci 2000;21:469-74.
-
(2000)
Trends Pharmacol Sci
, vol.21
, pp. 469-474
-
-
Murphy, G.J.1
Holder, J.C.2
-
42
-
-
0033741281
-
Expression of peroxisome proliferators-activated receptor (PPAR) gamma in gastric cancer and inhibitory effects of PPARgamma agonists
-
Sato H, Ishihara S, Kawashima K, Moriyama N, Suetsugu H, Kazumori H, Okuyama T, et al. Expression of peroxisome proliferators-activated receptor (PPAR) gamma in gastric cancer and inhibitory effects of PPARgamma agonists. Br J Cancer 2000;83:1394-400.
-
(2000)
Br J Cancer
, vol.83
, pp. 1394-1400
-
-
Sato, H.1
Ishihara, S.2
Kawashima, K.3
Moriyama, N.4
Suetsugu, H.5
Kazumori, H.6
Okuyama, T.7
-
43
-
-
0032746173
-
A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response
-
Su CG, Wen X, Bailey ST, Jiang W, Rangwala SM, Keilbaugh SA, et al. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 1999;104:383-9.
-
(1999)
J Clin Invest
, vol.104
, pp. 383-389
-
-
Su, C.G.1
Wen, X.2
Bailey, S.T.3
Jiang, W.4
Rangwala, S.M.5
Keilbaugh, S.A.6
-
44
-
-
0033925031
-
15-deoxy-delta (12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats
-
Kawahito Y, Kondo M, Tsubouchi Y, Hashiramoto A, Bishop-Bailey D, Inoue K, et al. 15-deoxy-delta (12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Invest 2000;106:189-97.
-
(2000)
J Clin Invest
, vol.106
, pp. 189-197
-
-
Kawahito, Y.1
Kondo, M.2
Tsubouchi, Y.3
Hashiramoto, A.4
Bishop-Bailey, D.5
Inoue, K.6
-
45
-
-
26244453309
-
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomized controlled trial
-
Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 2005;366:1279-89.
-
(2005)
Lancet
, vol.366
, pp. 1279-1289
-
-
Dormandy, J.A.1
Charbonnel, B.2
Eckland, D.J.3
Erdmann, E.4
Massi-Benedetti, M.5
Moules, I.K.6
|